- Previous Close
455.45 - Open
459.00 - Bid --
- Ask --
- Day's Range
456.80 - 469.15 - 52 Week Range
431.05 - 635.00 - Volume
92,084 - Avg. Volume
164,542 - Market Cap (intraday)
41.935B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
27.65 - EPS (TTM)
16.58 - Earnings Date Jan 22, 2025 - Jan 27, 2025
- Forward Dividend & Yield 1.00 (0.22%)
- Ex-Dividend Date Feb 6, 2024
- 1y Target Est
555.00
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.
www.aartidrugs.co.in1,064
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AARTIDRUGS.NS
View MorePerformance Overview: AARTIDRUGS.NS
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AARTIDRUGS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AARTIDRUGS.NS
View MoreValuation Measures
Market Cap
41.66B
Enterprise Value
47.27B
Trailing P/E
27.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.77
Price/Book (mrq)
3.25
Enterprise Value/Revenue
2.00
Enterprise Value/EBITDA
16.12
Financial Highlights
Profitability and Income Statement
Profit Margin
6.40%
Return on Assets (ttm)
6.17%
Return on Equity (ttm)
12.24%
Revenue (ttm)
23.8B
Net Income Avi to Common (ttm)
1.52B
Diluted EPS (ttm)
16.58
Balance Sheet and Cash Flow
Total Cash (mrq)
295.6M
Total Debt/Equity (mrq)
46.18%
Levered Free Cash Flow (ttm)
837.4M